LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

LLY

1,075.5

-2.49%↓

JNJ

221.67

-1.56%↓

ABBV

212.64

-2.44%↓

UNH

380.38

+0.46%↑

MRK

114.6

-3.37%↓

Home・Akcijų sąrašas・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.47 -0.68

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.44

Max

1.48

Pagrindiniai rodikliai
By Trading Economics
Pajamos	32M -8.3M
Pardavimai	-7.5M 37M
Pelnas, tenkantis vienai akcijai	-0.12
Pelno marža	-22.258
Darbuotojai	485
EBITDA	509K -38M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+59.73% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-90M 391M
Ankstesnė atidarymo kaina	2.15
Ankstesnė uždarymo kaina	1.47

Naujienos nuotaikos

By Acuity

50%

124 / 344 reitingas Healthcare

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-31 23:44; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

2026-05-31 23:36; UTC

Rinkos pokalbiai

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

2026-05-31 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

2026-05-29 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026-05-29 23:06; UTC

Įsigijimai, susijungimai, perėmimai

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026-05-29 20:53; UTC

Uždarbis

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026-05-29 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 20:33; UTC

Rinkos pokalbiai

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026-05-29 20:11; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 19:47; UTC

Uždarbis

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026-05-29 19:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026-05-29 19:22; UTC

Rinkos pokalbiai

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026-05-29 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026-05-29 18:19; UTC

Rinkos pokalbiai

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026-05-29 18:12; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026-05-29 18:11; UTC

Rinkos pokalbiai

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026-05-29 18:10; UTC

Rinkos pokalbiai

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026-05-29 17:55; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 17:55; UTC

Rinkos pokalbiai

NEAR Protocol Nearly Doubles in May -- Market Talk

2026-05-29 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026-05-29 17:00; UTC

Uždarbis

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026-05-29 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-29 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-29 16:02; UTC

Rinkos pokalbiai

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

59.73% į viršų

12 mėnesių prognozė

Vidutinis 2.38 USD 59.73%

Aukščiausias 3 USD

Žemiausias 1.5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Pacific Biosciences of California Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

124 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.